NLSP NLS Pharmaceutics AG: Year-over-year earnings per share growth for the last twelve months

Official company branding of NLS Pharmaceutics Ltd. (NLSP)

Will the commercialization of ADHD and narcolepsy treatments drive revenue growth for NLS Pharmaceutics AG (NLSP)? A quarterly snapshot of EPS growth reflects current trends, with the metric holding around 46.20. Simultaneously, the business is implementing "green chemistry" principles for the eco-friendly disposal of reagents. However, the lack of profitable products forces the company to rely on residual capital until clinical trials are completed.

NLS Pharmaceutics (NLSP) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 10/31/2025

Analytical breakdowns for NLS Pharmaceutics AG

- share price and consensus valuation forecast:
Stock Quotes NLS Pharmaceutics|NLSP - Analyst Consensus Forecast
- company stock capitalization data:
Market Value NLS Pharmaceutics AG|NLSP - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share NLS Pharmaceutics|NLSP - Total Stockholders' Equity|Market Value to Book Value Ratio nlspharma.com|NLSP - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity NLS Pharmaceutics AG|NLSP - Long-Term Liabilities to Capital|Short-Term Debt to Capital NLS Pharmaceutics Ltd.|NLSP - Company Total Indebtedness|Debt to Book Value NLS Pharma|NLSP - Long-Term Debt|Company Short-Term Debt NLS Pharmaceutics|Quick Liquidity nlspharma.com
- earnings and market multiples details:
NLSP - Company Net Income|Expected Profit NLS Pharmaceutics AG|NLSP - Business Payback Period|Projected Price to Earnings NLS Pharma|NLSP - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharmaceutics|NLSP - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) NLS Pharmaceutics|NLSP - Earnings per share for the trailing year|Quarterly EPS earnings growth nlspharma.com|NLSP - Earnings growth in current year|Net earnings per share growth forecast for next year NLS Pharmaceutics AG
- sales volume and revenue indicators:
NLSP - Company Sales Revenue|Company Projected Revenue NLS Pharma|NLSP - Market Cap to Revenue|Forward P/S Multiple NLS Pharmaceutics|NLSP - Sales Growth YoY (TTM)
Fundamental company analysis:NLS Pharmaceutics Ltd., NLSP
Manufactured product of NLS Pharmaceutics AG

The speculative nature of the NLS Pharmaceutics AG (NLSP) biotech business, which depends on ADHD patents and regulatory risks, renders the company's financial stability extremely volatile. The quarterly EPS progress trend reflects the percentage change in net income per share compared to the same period, allowing investors to filter out market noise and assess real profit scalability amid funding shortages.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals PLC) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Corp (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics, Inc.|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Corp (CNTA)|Year-over-year earnings per share growth for the last twelve months DYN (Dyne Therapeutics Inc)|Year-over-year earnings per share growth for the last twelve months Edgewise Pharma EWTX|Rapport Corp - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Therapeutics|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Larimar Pharma LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Entrada TRDA|Quarterly EPS earnings growth PTHS|Year-over-year net earnings per share growth for the last 12 months MediciNova MNOV|Year-over-year earnings per share growth for the last twelve months Serina Therapeutics SER|Year-over-year net earnings per share change for the last twelve months BioXcel Therapeutics Inc (BTAI)|PMN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Apimeds Pharmaceuticals US APUS|AEON Biopharma (AEON) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma|Quarterly EPS earnings growth Reata